(Q38217723)

31 August 2017

Immunomodulatory adjuvant therapy in severe community-acquired pneumonia (English)

1 reference

31 August 2017

0 references

Shaun Harry Pennington

series ordinal

2

0 references

Ben Morton

object named as

Ben Morton

series ordinal

1

0 references

Stephen B. Gordon

object named as

Stephen B Gordon

series ordinal

3

0 references

publication date

5 June 2014

1 reference

Expert Review of Respiratory Medicine

31 August 2017

1 reference

31 August 2017

8

1 reference

31 August 2017

5

1 reference

31 August 2017

587-596

1 reference

Pneumonia in low and middle income countries: progress and challenges.

31 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Drotrecogin alfa (activated) in adults with septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Anti-inflammatory effects of statins: clinical evidence and basic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Statins and associated risk of pneumonia: a systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Role of acute infection in triggering acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Immunomodulatory effects of macrolides during community-acquired pneumonia: a literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Differential effects of three antibiotics on T helper cell cytokine expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

BTS guidelines for the management of community acquired pneumonia in adults: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Single versus combination antibiotic therapy in adults hospitalised with community acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Evolution and molecular characterization of macrolide-resistant Streptococcus pneumoniae in Canada between 1998 and 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

A meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Antibiotic prevention of acute exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Hydrocortisone therapy for patients with septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Early Corticosteroids in Severe Influenza A/H1N1 Pneumonia and Acute Respiratory Distress Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Dexamethasone downregulates the systemic cytokine response in patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Impact of systemic corticosteroids on the clinical course and outcomes of patients with severe community-acquired pneumonia: A cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Analysis of systemic corticosteroid usage and survival in patients requiring mechanical ventilation for severe community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

What is the role of steroids in pneumonia therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Relationship between neutrophil elastase and acute lung injury in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

ONO-5046, a novel inhibitor of human neutrophil elastase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Intravenous immunoglobulin: striving for appropriate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Drotrecogin alfa (activated)...a sad final fizzle to a roller-coaster party

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Measurement of monocytic HLA-DR (mHLA-DR) expression in patients with severe sepsis and septic shock: assessment of immune organ failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Purification and Biological Activity of Thymosin, a Hormone of the Thymus Gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Thymosin alpha 1: past clinical experience and future promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Harnessing the biology of IL-7 for therapeutic application

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Passive antibody therapy for infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

THE RESULTS OF THE SERUM TREATMENT IN THIRTEEN HUNDRED CASES OF EPIDEMIC MENINGITIS

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

A functional epitope of the pneumococcal surface adhesin A activates nasopharyngeal cells and increases bacterial internalization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

P4-mediated antibody therapy in an acute model of invasive pneumococcal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Immunotherapy with a combination of intravenous immune globulin and p4 peptide rescues mice from postinfluenza pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

P4 peptide therapy rescues aged mice from fatal pneumococcal sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

A 28-aa pneumococcal surface adhesin A-derived peptide, P4, augments passive immunotherapy and rescues mice from fatal pneumococcal infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

A Novel Innate Immune-Enhancement Strategy Combined with IVIG Rescues Mice from Fatal Staphylococcus aureus Septicemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

Immunoactivating peptide p4 augments alveolar macrophage phagocytosis in two diverse human populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.927736

10.1586/17476348.2014.927736

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference

PubMed ID

24898699